Table 17. Comparison 5: nortriptyline versus placebo: global functioning.
| Study | Outcome (mean scores) | Experimental group baseline (see note 1) | Experimental group endpoint (n=11) (see note 1) | Control group baseline (see note 1) | Control group endpoint (n=9) (see note 1) | Statistic (see note 2) |
|---|---|---|---|---|---|---|
| Powell 1995 | Global functioning (GAS-high)b | 59.3 | 77.1 | 57.9 | 75.7 | favours neither condition |
| Powell 1995 | Global functioning (GAS-low)b | 37.6 | 51.7 | 34.8 | 43.0 | favours neither condition |
| Powell 1995 | Global functioning (SCL-90 GSI subscale)a | 1.0 | 0.3 | 0.8 | 0.7 | favours neither condition |
GAS = Global Assessment Scale; SCL-90 = Symptom Check List-90; GSI = global severity index
a
high scores indicate greater severity.
b
high scores indicate better functioning.
1. standard deviations not reported.
2. trend-over-time analyses based on measurements at baseline and six months with additional measurements at 2, 4, and 6 weeks, then at 2, 3, 4, and 5 months; analyses conducted by trial investigators